Job description:
 

We are currently recruiting for a Scientist III to join the Analytical Development and QC team. The purpose of this role is to perform and report laboratory-based experiments, in accordance with scientific or regulatory requirements within Containment Level 2 and Containment Level 3 laboratories.

Our ADQC team supports the development of products through analytical testing to facilitate manufacturing and process development, ensuring appropriate quality controls and use of analytics.

Your responsibilities in this role would be:

• Performing analytical testing as part of QC release
• Assisting in the development of assays when required
• Conduct investigations in accordance with correct methodologies and procedures under the direction of Subject Matter Expert/QC Manager/Line Manager

• Ensuring a high standard of record keeping and documentation of assays and investigations.
• Presentation of scientific data at internal meetings.
• Providing training in laboratory procedures.

• Responsible for the completion of tasks about their criticality.
• Responsibility for maintenance and compliance of a GxP laboratory area and/or important equipment
• Work will be conducted in accordance with the OXB Quality Management system.
• Writing and reviewing of departmental documentation and SOP’s.
• Completion of Quality records (Change control, Deviation, and CAPAs) to a high level in a timely manner

We are looking for:

• Educated to a minimum of BSc Degree with basic experience of working in a related environment.
• An understanding of Virology and gene therapy would be an advantage.
• Demonstratable competency in performing laboratory tasks and general experimental procedures with expertise in a single area.
• Laboratory technical experience in cell culture, qPCR and molecular biology.
• Understanding of laboratory health and safety requirements.
• Capable of offering reasonable solutions to assay and equipment troubleshooting.
• Good working knowledge of regulatory requirements, e.g. GMP, GLP, GCP and/or Validation and Quality Management systems.
• Competent in training operators in complex methods

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment, and teamwork, and so can you.

Collaborate. Contribute. Change lives

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.